Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-09-06 | Symphogen (Denmark) | |||
2012-09-14 | secretin human | RepliGen Europe (Ireland) | pancreatic duct visualization for the detection of duct abnormalities | |
2012-09-18 | [2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide] | Algiax Pharmaceuticals (Germany) | traumatic spinal cord injury | |
2012-09-18 | Asp-Arg-Val-Try-Ile-His-Pro | Tarix Pharmaceuticals (USA) | acute lung injury |
Granting of a patent |
2012-09-18 | mavoglurant | Novartis (Switzerland) | fragile X syndrome | |
2018-03-22 | rucaparib | Clovis Oncology UK - Clovis Oncology (USA) | ovarian cancer | Positive opinion for the granting of a Market Authorisation in the EU |
2012-10-10 | alpha-1 proteinase inhibitor (for inhalation use) | Grifols (Spain) | cystic fibrosis |
Granting of the orphan status in the EU |
2012-10-10 | humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor | Novo Nordisk (Denmark) | hemophilia A |
Granting of the orphan status in the EU |
2012-09-18 | mixture of two allogeneic human pancreatic cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase gene | European Medical Advisory Services Limited (UK) | pancreatic cancer | |
2014-12-24 | obinutuzumab | Genentech, a member of Roche Group (USA - CA - Switzerland) Roche (Switzerland) | chronic lymphocytic leukaemia (CLL) |
Granting of a Market Authorisation in the US |
2012-09-18 | recombinant human lecithin cholesterol acyltransferase | Alphacore Pharma (USA) | familial lecithin cholesterol acyltransferase deficiency (LCAT) |
|
2012-09-18 | liposomal daunorubicin | Galen Limited (UK) | acute myeloid leukaemia | |
2012-09-20 | vortioxetine (Lu AA21004) | Lundbeck (Denmark) | major depression | Product launch |
2012-09-20 | CLC-1280 | Cardiolynx (Switzerland) | angina pectoris | |
2012-09-20 | low dose contraceptive patch (ethinylestradiol/ gestodene) | Bayer (Germany) | contraception |
Submission of a Market Application in the EU |
2012-09-21 | concentrate of proteolytic enzymes enriched in bromelain | Teva Pharmaceuticals (Israel) | removal of eschar in adults with deep partial- and full-thickness thermal burns | |
2012-09-21 | ingenol mebutate | Leo Pharma (Denmark) | actinic keratosis | |
2012-09-21 | apixaban | BMS (USA - NY) Pfizer (USA - NY) | prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
Granting of a Market Authorisation in the US |
2012-09-21 | bevacizumab | Roche (Switzerland) | treatment of adult patients with first recurrence of platinum-sensitive epithelian ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents | Granting of a Market Authorisation in the EU |
2012-10-26 | linagliptin | Boehringer Ingelheim (Germany) - Eli Lilly (USA) | type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control |
Granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+